Infinity Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.53 Insider Own0.30% Shs Outstand89.16M Perf Week106.76%
Market Cap128.26M Forward P/E- EPS next Y-0.55 Insider Trans0.00% Shs Float88.16M Perf Month129.66%
Income-46.80M PEG- EPS next Q-0.09 Inst Own44.30% Short Float1.59% Perf Quarter173.90%
Sales2.20M P/S58.30 EPS this Y21.80% Inst Trans-1.41% Short Ratio1.98 Perf Half Y35.40%
Book/sh-0.01 P/B- EPS next Y-15.30% ROA-59.60% Target Price6.17 Perf Year-51.12%
Cash/sh0.67 P/C2.27 EPS next 5Y- ROE-299.00% 52W Range0.46 - 3.89 Perf YTD-32.00%
Dividend- P/FCF- EPS past 5Y2.70% ROI- 52W High-60.67% Beta2.01
Dividend %- Quick Ratio4.20 Sales past 5Y-37.00% Gross Margin39.70% 52W Low232.25% ATR0.13
Employees33 Current Ratio4.20 Sales Q/Q40.00% Oper. Margin- RSI (14)85.77 Volatility23.80% 13.02%
OptionableYes Debt/Eq- EPS Q/Q-5.80% Profit Margin- Rel Volume4.36 Prev Close1.27
ShortableYes LT Debt/Eq- EarningsAug 09 AMC Payout- Avg Volume706.13K Price1.53
Recom1.90 SMA2091.16% SMA50106.20% SMA20020.99% Volume3,079,023 Change20.47%
Oct-18-21Initiated H.C. Wainwright Buy $9
Aug-02-21Upgrade JP Morgan Neutral → Overweight $6
Jul-28-21Upgrade Wells Fargo Equal Weight → Overweight $4 → $14
Jul-07-21Resumed B. Riley Securities Buy $7
Mar-18-21Initiated Truist Buy $12
Feb-18-21Initiated Piper Sandler Overweight $7
Feb-05-21Upgrade JP Morgan Underweight → Neutral
Jun-27-19Initiated Oppenheimer Outperform
Jan-04-19Initiated B. Riley FBR Buy $3
Nov-12-18Downgrade Wells Fargo Outperform → Market Perform
Nov-12-18Downgrade JP Morgan Neutral → Underweight
Oct-12-17Upgrade Wells Fargo Market Perform → Outperform
Aug-10-16Reiterated Wedbush Neutral $1.25 → $1
Jun-15-16Downgrade Wells Fargo Outperform → Market Perform
Jun-15-16Downgrade RBC Capital Mkts Outperform → Sector Perform $12 → $2
Jun-15-16Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-15-16Downgrade Jefferies Buy → Hold
Jun-14-16Downgrade JP Morgan Overweight → Neutral
Jun-14-16Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jun-14-16Downgrade FBR Capital Outperform → Mkt Perform $15 → $2
Aug-13-22 08:33AM  
Aug-09-22 06:25PM  
Aug-02-22 08:25AM  
May-19-22 01:16PM  
May-17-22 08:35AM  
May-03-22 05:45PM  
Apr-26-22 08:25AM  
Apr-08-22 04:05PM  
Apr-04-22 05:31PM  
Mar-29-22 08:15PM  
Mar-24-22 07:00AM  
Mar-22-22 07:35AM  
Mar-21-22 08:25AM  
Mar-17-22 07:00AM  
Mar-09-22 08:35AM  
Mar-07-22 05:25PM  
Feb-24-22 08:15AM  
Feb-01-22 07:03AM  
Jan-20-22 08:35AM  
Jan-06-22 08:35AM  
Jan-05-22 07:05AM  
Dec-14-21 07:35AM  
Dec-13-21 08:35AM  
Dec-10-21 07:58AM  
Dec-06-21 08:35AM  
Nov-30-21 06:37AM  
Nov-26-21 08:30AM  
Nov-22-21 08:35AM  
Nov-02-21 06:15PM  
Oct-26-21 07:35AM  
Oct-18-21 05:22PM  
Oct-01-21 09:27AM  
Sep-13-21 08:35AM  
Sep-07-21 07:35AM  
Sep-02-21 08:35AM  
Aug-23-21 08:32AM  
Aug-04-21 12:00PM  
Aug-03-21 08:00AM  
Aug-02-21 06:07PM  
Jul-31-21 02:48PM  
Jul-28-21 12:05PM  
Jul-27-21 10:40AM  
Jul-22-21 03:03PM  
Jul-20-21 08:35AM  
Jun-14-21 08:35AM  
Jun-03-21 04:39AM  
May-28-21 04:17AM  
May-13-21 06:35PM  
May-06-21 07:35AM  
May-05-21 08:35AM  
May-03-21 03:01PM  
Apr-27-21 08:35AM  
Apr-13-21 08:59AM  
Mar-29-21 03:22AM  
Mar-19-21 08:47AM  
Mar-16-21 05:35PM  
Mar-10-21 08:35AM  
Mar-09-21 04:01PM  
Mar-02-21 08:35AM  
Feb-20-21 07:40AM  
Feb-18-21 10:02AM  
Feb-12-21 08:30AM  
Feb-11-21 04:01PM  
Feb-10-21 04:05PM  
Jan-20-21 12:00PM  
Jan-15-21 08:35AM  
Jan-11-21 08:53AM  
Jan-07-21 10:51AM  
Jan-06-21 09:11AM  
Dec-27-20 02:34AM  
Dec-09-20 12:25PM  
Dec-07-20 07:35AM  
Dec-02-20 09:47PM  
Nov-17-20 09:22AM  
Nov-12-20 05:53AM  
Nov-09-20 06:35PM  
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.